Misonix Supports Uganda Spine Mission For Fifth Consecutive Year

FARMINGDALE, N.Y., Aug. 11, 2016 /PRNewswire/ — Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, neurosurgery, wound debridement, skull based surgery, laparoscopic surgery and other surgical applications, announced its annual support for the Uganda Spine Surgery Mission organized by leading spine surgeon Isador Lieberman, MD, from the Texas Back Institute in Plano, Texas.

Dr. Lieberman and Dr. Mark Kayanja, who is originally from Uganda, founded the Uganda Spine Surgery Mission (www.ugandaspinesurgerymission.com) in 2006 with the purpose of providing advanced spine care to Ugandan patients afflicted by infectious, degenerative, traumatic and congenital spinal ailments. Additionally, the mission’s goals include striving to provide a fertile environment for the education of those who serve these patients.

A collaborative effort between a team of top spine surgeons, this year’s mission evaluated over 200 cases while more than 40 of these cases were selected for surgery. BoneScalpel^® advocates, and users, Dr. Lieberman and Dr. Michael Hisey of the Texas Back Institute, and Dr. Paul Holman, Director of Neurosurgery at Houston Methodist Spine Center in Houston, Texas, were among the group of leading surgeons who volunteered their time and expertise toward this philanthropic effort.

“Misonix has remained dedicated to the Uganda Spine Surgery Mission providing world class medical devices with strong customer support. The precise control of the BoneScalpel has enabled the team to perform the most complex of surgeries under the most trying of circumstances without any issues,” said Dr. Lieberman.

This year’s mission marks the fifth consecutive year Misonix has dedicated its support, underscoring the company’s admiration of the mission’s continuous achievements in addition to the surgical team’s relentless pursuit toward their lofty vision and goals.  “Misonix has provided unconditional support in our efforts to help many underprivileged individuals return to living an active and healthy life,” Dr. Lieberman commented.

Scott Ludecker, Senior Vice President of Misonix, said, “We’re happy to be able to support the great work of the Uganda Spine Surgery Mission and continue to pledge our support as the mission’s goals and values mirror those of Misonix, in that their dedication is fueled by their commitment to improving patient lives. Operating under less than ideal circumstances, the BoneScalpel allows these surgeons to be able to perform spine surgery that is safe, efficient and impactful. We want to thank Dr. Lieberman, the mission’s many spine surgeons and medical staff for their charitable work in Uganda. Their selfless effort to help the less fortunate continues to be an inspiration to us all.”

Clinically, the benefits that BoneScalpel provides are amplified when used in such limited surgical settings like those found in Uganda.  The increased surgical efficiencies of BoneScalpel such as precision cutting and the ability to reduce blood loss while sparing soft tissue provides invaluable benefits that include the reduced need for blood transfusions as well as a reduction in operating time.

Mr. Ludecker concluded, “The clinical and economic value of the BoneScalpel in spine surgery is well established in many of the world’s most esteemed hospitals. It’s rewarding to know that those patients in Uganda are able to benefit equally from our technology.  We are humbled to be able to work with Dr. Lieberman, and his team, in their noble work.”

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix’s proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Logo – http://photos.prnewswire.com/prnh/20160201/328020LOGO

SOURCE Misonix, Inc.